The platform
One platform, predicting cancer genetics from every image.
IGX Predict™ predicts driver mutations directly from the H&E pathology slides already in your workflow, returning actionable results in 24 hours, at a fraction of the cost of sequencing, without consuming additional tissue.
1st patented AI cancer mutation platform, globally.
How it works
From stained slide to scored mutation map.
No DNA extraction, no sequencing run, no additional tissue. IGX Predict™ analyzes the whole-slide image and surfaces the driver mutations that guide targeted therapy and trial matching.
- ScanDigitize the H&E whole-slide image on your existing scanner.
- PartitionThe image is divided into thousands of small tiles.
- ScoreA deep-learning model scores every tile for the morphological signatures of driver mutations.
- AggregateTile scores resolve into a slide-level mutation probability and a spatial heatmap.
- ConfirmPredicted mutations can be confirmed with a targeted single-gene or panel assay.
The engines
IGX Clear, Seek, and Focus: clean up, then choose.
Everything runs under the IGX Predict™ platform. Three engines prepare and sort each case before a product ever runs, so the same slide can be tuned toward sensitivity or specificity for the job at hand.
IGX Clear
Clean the input
Normalizes staining, scanner make, and resolution, and removes artifacts, so accuracy holds across sites, labs, and scanners.
The foundation under every prediction
IGX Seek
High sensitivity, catch every positive
Tuned to find every positive and enrich the mutation-positive pool, speeding up confirmatory testing.
For screening and clinical-trial enrichment
IGX Focus
High specificity, most reliable call
Minimizes false positives for the most reliable mutation-present call.
For clinical trials and companion diagnostics
Dial sensitivity or specificity to the job, same slide, same platform.
The products
One platform. Four products. Four cancer types.
Once a case is cleaned and sorted, IGX Predict™ runs the matching product. Each is a focused, clinically grounded module, not a broad foundation model, trained to predict the mutations that matter for one cancer, all from the same H&E slide.
Pulmogene Commercial 2026
Predicts the driver mutations that direct first-line targeted therapy in lung adenocarcinoma.
Markers EGFR · KRAS · TP53 · STK11 · FAT1 · SETBP1
BLISS In development, pilot
Self-supervised breast module mapping the histomorphological signatures of driver mutations, including the actionable AKT1 hotspot and PIK3CA.
Markers PIK3CA · AKT1 · ESR1 · BRCA1/2 · TMB
NeuroInsight On roadmap
Predicts the alterations that define adult diffuse glioma from neuropathology slides, shaped by molecular neuropathology expertise.
Markers IDH 1/2 · 1p/19q codeletion · ATRX
DermPredict On roadmap
Surfaces melanoma drivers, including BRAF, from routine dermatopathology whole-slide images.
Markers BRAF · NRAS · c-KIT · TMB
Four products across four cancer types. Breast is covered by BLISS, which now includes the actionable AKT1 hotspot alongside PIK3CA and other drivers.
Flagship product
Pulmogene, live for lung adenocarcinoma.
Our first commercial product predicts the lung drivers that direct first-line therapy, straight from the H&E slide, with a spatial map showing where each signal is strongest.
Representative Pulmogene output, one lung adenocarcinoma case. Illustrative, not a performance figure.
Custom models
Need a target that isn't on the list?
The four products cover lung, breast, brain, and skin, but the platform is not limited to them. For biopharma and diagnostic partners, we build custom IGX Predict™ models trained to predict a specific mutation, biomarker, or cancer type of interest, using the same engines and the same standard H&E slide.
Integration
Runs inside the digital pathology workflow you already have.
IGX Predict™ AI models can be integrated into all major Image Management Systems. The platform is fully IMS-agnostic.
Your slides, your scanner
IGX Predict™ reads the H&E whole-slide images your lab already produces. No new tissue, no new stain, no change to how cases are prepared.
Connected to your viewer
Integrates with the digital pathology platforms and scanners you already use, including Proscia, PathPresenter, Philips, and Leica, so predicted mutations and heatmaps land where pathologists already review their cases.
Featured integration partner: Proscia. Deployed in live oncology trial workflows alongside PathPresenter.
Validation
Measured against sequencing, case after case.
IGX Predict™ is for Research Use Only and does not substitute for molecular testing. Predicted mutations should be confirmed with a validated assay. Performance varies by product; see each product report for validation detail.
Who it is for
Two ways to put IGX Predict™ to work.
For pathology practices
Add molecular insight to routine sign-out, screen more cases for targeted therapy, and reduce reliance on costly send-outs.
For biopharma partners
Accelerate trial enrollment with rapid, tissue-sparing mutation screening that scales across distributed sites.
See IGX Predict™ on your slides.
Run a case, pilot the platform, or scope an integration with your team.
Imagenomix Corp · New York, NY · Contact